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Background: Patients’ general tendency to adhere to health care provider-recommended 
treatments is associated with a number of health outcomes, but whether it influences pain 
severity over time among individuals with cancer is unclear. We explored the relationship 
between adherence tendency and subsequent pain severity among cancer patients participating 
in a randomized controlled trial of coaching to enhance communication with physicians and 
reduce pain severity.
Methods: Associations between baseline Medical Outcomes Study general adherence measure 
score and pain severity over 12 weeks were examined with repeated-measures regression models. 
Model 1 included sociodemographics, study group and site, follow-up point, and baseline pain; 
Model 2 included these variables plus partner status, physical and mental health status (12-item 
Short Form Health Survey [SF-12®]), and pain control self-efficacy.
Results: Of 307 patients randomized, 224 (73%) had at least one follow-up pain severity 
assessment plus complete data for other model variables and were included in the analyses. 
In Model 1, adherence tendency was associated with less subsequent pain severity: a one 
standard deviation increase in adherence tendency was associated with a 0.22-point adjusted 
mean decrease in pain severity on a 0–10 scale (95% confidence interval 0.40, 0.03). The 
association was diminished and not statistically significant in Model 2, primarily due to 
adjustment for the SF-12.
Conclusion: Tendency to adhere to provider-recommended treatments was associated with 
subsequent pain severity among individuals with cancer, suggesting a potential way of predict-
ing and intervening to improve cancer pain control. However, the association was attenuated 
after adjusting for health status, suggesting mediation or confounding of the relationship by 
health status.
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Suboptimal pain control is common among individuals with cancer.1,2 However, 
whether a patient’s general tendency to adhere to health care provider-recommended 
treatments influences cancer pain severity over time is unclear, as no studies have 
examined this issue. This is an important research gap for several reasons. Data from 
cross-sectional studies suggest low adherence to both scheduled and “as needed” anal-
gesics prescribed for cancer pain.3,4 Although there appear to be multiple contributors 
to this problem,1,5 patient concerns regarding the potential side effects (eg, lethargy) 
and risks (eg, addiction) of analgesics prescribed for cancer pain are likely to play a 
role. Such concerns appear to be prevalent in society1,2,6,7 and, among those endorsing 
them, might lessen their tendency to adhere to recommended analgesic regimens.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Low adherence to analgesics would, in turn, be expected to 
contribute to suboptimal cancer pain control, given that poor 
treatment adherence has been associated with worse outcomes in 
numerous studies involving health conditions other than   cancer 
pain.8 Taken together, these observations suggest the impor-
tance of studying the relationship between patient tendency 
to adhere and subsequent cancer pain control.   Additionally, 
although the phrase “tendency to adhere” may imply a largely 
fixed dispositional characteristic, prior intervention studies 
involving health conditions other than cancer pain have estab-
lished that tendency to adhere can be favorably influenced,9 so 
may have both “trait” and “state” components. Thus, if a greater 
tendency to adhere was associated with reduced cancer pain 
severity over time, it might be a useful target for interventions 
aimed at improving cancer pain control.
To begin to examine these issues, we conducted second-
ary prospective observational analyses of data from Cancer 
Health Empowerment for Living without Pain (Ca-HELP), 
a randomized controlled trial (RCT) of a patient coaching 
intervention, designed to enhance patient communication 
with cancer physicians and help them cope with and man-
age cancer-related pain.10 The coaching intervention led to 
more active pain-related communication by patients11 but no 
improvement in the general tendency to adhere to provider-
recommended treatments, as measured with the well vali-
dated Medical Outcomes Study (MOS) general adherence 
self-report measure,12,13 and no decrease in subsequent pain 
(unpublished data). In the current analyses, we examined 
the relationship between a general tendency to adhere to 
  provider-recommended treatments at baseline and cancer 
pain severity at 2, 6, and 12 weeks after the baseline assess-
ment. Based on the preponderance of prior evidence from 
studies involving patients with health conditions other than 
cancer,8 we hypothesized that a higher general tendency to 
adhere to recommended treatments at baseline would inde-
pendently predict lower cancer pain severity over time.
We examined two main models, sequentially adjusting for 
different groupings of covariates that have been associated 
with pain14–21 and adherence22–36 in prior studies. Model 1 
included baseline pain severity, basic sociodemographic 
characteristics (age, gender, race/ethnicity, and education) 
as well as RCT-related variables that might confound the 
adherence tendencies/pain relationship (study group, study 
site, pain follow-up time point). Model 2 included all Model 1 
variables plus characteristics that might influence adherence 
tendency, pain, or both: partner status, cancer type and degree 
of spread, physical and mental health status, and pain control 
self-efficacy. We also conducted a cross-lagged regression 
analysis (regressing baseline pain severity on to adherence 
tendency measured at 6 week follow-up, regressing 6 week 
pain severity on baseline adherence tendency and then com-
paring the two resulting cross-lagged regression coefficients 
for adherence) in order to assess the directionality of the 
relationship between tendency to adhere and pain severity. 
Finally, we examined the effects of individually removing 
these variables from Model 2, to facilitate exploration of 
which might most strongly influence the association between 
tendency to adhere and pain severity.
Methods
Study activities were conducted from November 2006 to 
December 2008. The Institutional Review Boards affiliated 
with the three participating institutions granted approval for the 
study. The trial was registered at ClinicalTrials.gov (identifier 
NCT00283166). The funder (American Cancer Society) had 
no role in the collection, analysis, or interpretation of data.
In the parent RCT, tailored education and coaching were 
compared with enhanced usual care. Full details of the study 
methods have been published elsewhere.10 Here, we focus on 
methodological issues relevant to the current observational 
analyses.
Patient recruitment, enrollment,  
and randomization
Oncology physicians (N = 49) were recruited from three 
health care delivery systems in the greater Sacramento, 
California, USA, area: the University of California Davis, 
Kaiser-  Permanente, and the Northern California Veterans 
Administration. Potentially eligible patients, identified from 
each practice using computer-generated lists, were mailed a 
study invitation letter along with a postage-paid postcard allow-
ing them to opt out of the study if desired. All patients who 
had not returned the postcard within 3 weeks were contacted 
by phone, screened for eligibility, and invited to participate. 
Initial patient eligibility criteria were age 18–80 years, intact 
cognition, able to speak English, and having one of eight can-
cer types (lung, breast, prostate, head and neck, esophageal, 
colorectal, bladder, and various gynecologic). To further deter-
mine potential eligibility, responding patients also answered 
two pain-related questions. The first question asked them to 
indicate their worst (eg, most severe) level of pain during the 
2 weeks prior to assessment using a 0–10 analog scale, with 0 
representing no pain and 10 representing the worst pain imagin-
able. The second question asked them to indicate the degree to 
which pain had interfered with their usual daily activities over 
the 2 weeks prior to assessment on a 1–5-point Likert scale, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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with 1 representing no interference and 5 representing extreme 
interference. To be eligible for the study, participants had to 
have a response of 4 or greater to the first item, or a response 
of 3 or greater to the second item, or both. Patient exclusion 
criteria included major surgery scheduled within 6 weeks, 
enrollment in a hospice, being followed by a pain management 
service (beyond a single consultation), or inability to receive 
and/or complete mailed enrollment materials.
Patients meeting eligibility criteria and lacking exclusion 
criteria were enrolled and randomly assigned to tailored edu-
cation and coaching or enhanced usual care. Enrolled patients 
were promised $40 after completing the index study visit, 
and a second $40 following completion of three scheduled 
follow-up data collection phone calls.
study visit procedures
Patients were asked to arrive at their oncology office 1 hour 
prior to a scheduled appointment. On arrival, they were 
greeted by a trained health educator, who brought them to 
a quiet space, obtained written informed consent, and pro-
vided a pre-intervention questionnaire. The health educator 
then administered the patient’s randomly assigned interven-
tion, either tailored education and coaching intervention or 
enhanced usual care (control).10 Patients then completed 
a post-intervention, pre-visit questionnaire, attended their 
physician visit, and then completed a post-visit questionnaire. 
Follow-up questionnaires were administered via telephone 
at 2 weeks, 6 weeks, and 12 weeks after baseline.
Measures
Adherence
General tendency to adhere to provider-recommended 
treatments was assessed at the time of study enrollment and 
again at 6 week follow-up using the MOS general adherence 
measure.12,13 The measure has been used successfully in prior 
studies,13,33,37,38 including the Medical Outcomes Study for 
which it was developed,13 as have slightly reworded HIV- 
and tuberculosis-specific versions.39,40 Scores on the measure 
have been significantly correlated with adherence to specific 
medications measured using a variety of approaches, includ-
ing via electronic pill bottle monitoring devices.33,37,40 The 
five measure items as employed in the study are shown in 
Figure 1. A 6-point Likert response scale was used for all 
items, from 1 = none of the time to 6 = all of the time. Scores 
for individual items were averaged to yield a summary score 
ranging from 1 to 6, with higher scores indicating better 
adherence. Cronbach’s α for the measure in our sample was 
0.80 at baseline and 0.89 at 6 weeks.
Pain severity
Pain severity was measured at study enrollment (the baseline 
value in our analyses), immediately pre-intervention, imme-
diately post-intervention (but before the study oncologist 
visit), immediately post-visit, and at 2, 6, and 12 weeks. 
At each measurement point, pain severity was coded as 
the mean of average and worst reported pain over the prior 
2 weeks, both assessed with 0–10 analog scales, with 0 
representing no pain and 10 representing the worst pain 
imaginable.10 Cronbach’s α for the combined pain severity 
measure was 0.88, 0.87, 0.88, 0.89, 0.90, and 0.93 at pre-
intervention, post-intervention, post-visit, and 2, 6, and 12 
weeks, respectively.
Other measures
Measures to assess variables that might influence or con-
found the relationship between adherence and pain severity 
How often was each of the following statements true for you during the past 4 weeks?
1. I had a hard time doing what the doctor suggested I do.
2. I found it easy to do the things my doctor suggested I do.
3. I was unable to do what was necessary to follow my doctor’s treatment plans.
4. I followed my doctor’s suggestions exactly.
*****
5. Generally speaking, how often during the past 4 weeks were you able to do what the doctor
told you? 
Figure 1 Medical Outcomes study (MOs) general adherence measure items. items 2, 4, and 5 were reverse coded.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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were also included. Basic demographic characteristics (age, 
race/ethnicity, sex, education level) were assessed using 
administrative records and the study screening and enroll-
ment interviews. Participants were also asked at enrollment 
whether or not they were living with a partner. Cancer type 
(diagnosis) and stage were obtained via medical record 
review using a standardized medical record abstraction 
form. Mean inter-rater agreement (kappas) for abstraction 
of clinical data was 0.94 (range 0.84–1.0). Medical record 
abstractors also recorded the status of chemotherapy, hor-
monal therapy, radiotherapy, and surgical therapy for each 
patient. For surgical therapy, discrete status categories were 
scheduled to receive within 3 months, previously received, 
or none/status unknown. For the other three therapies, status 
categories were currently receiving/scheduled to begin within 
2 weeks, previously received, or none/status unknown.
Health status was measured during the enrollment inter-
view with the extensively validated MOS 12-item Short 
Form Health Survey (SF-12®) measure, from which Physi-
cal Component Summary (PCS-12) and Mental Component 
Summary (MCS-12) scores were derived.41–43 SF-12 items 
were scored and normalized via a standardized algorithm to 
calculate PCS-12 and MCS-12 scores ranging from 0 to 100, 
with higher scores indicating better functioning. The MCS-12 
and PCS-12 were designed to have mean scores of 50 and 
standard deviations of 10 in a representative sample of the 
US population.44
Finally, pain control self-efficacy was assessed at enroll-
ment using three items drawn from the self-efficacy for pain 
management subscale of the Chronic Pain Self-Efficacy 
Scale.45 A 5-point Likert response scale was used for each 
item, from 1 = not at all certain to 5 = extremely certain; 
Cronbach’s α in this sample was 0.67.
statistical analysis
Analyses were conducted using Stata (Version 11,   StataCorp, 
College Station, TX, USA). Because of unmeasured influ-
ences, patient pain severity trajectories over time might 
be systematically underestimated or overestimated by our 
regression model, invalidating the important assumption 
that residual errors are independent. To account for this, we 
used mixed-effects regression models that included patient-
specific varying (random) intercepts to assess the fixed effects 
of adherence and other independent variables on subsequent 
mean pain severity levels.46 The key dependent variables were 
pain severity at each of the four follow-up assessments (post-
visit and 2, 6, and 12 weeks). The key independent variable 
was general adherence tendency at enrollment.
We employed a sequential modeling approach to explore 
the effects of adjusting for different groupings of covari-
ates on the adherence/pain relationship. Model 1 included 
age category (10 year increments); gender; minority status 
(subjects self-identifying as other than non-Hispanic White 
  [minority] versus those self-identifying as non-Hispanic 
White   [non-minority], based on crossing responses to 
separate race and ethnicity questions); years of education 
(,12, 13–15, and .16); study group (experimental versus 
control); study site; baseline pain severity; and pain assess-
ment time point. Model 2 included all Model 1 variables 
plus cancer type (lung, breast, prostate, head and neck, 
esophageal, colorectal, bladder, or gynecologic) and stage 
(metastatic or not), partner status (present versus absent), 
physical (PCS-12) and mental (MCS-12) health status, and 
pain control self-efficacy.
To address the directionality of the relationship between 
tendency to adhere and pain severity, we also performed a 
cross-lagged panel regression analysis by fitting two ordi-
nary least squares (OLS) regression models and comparing 
the cross-lagged coefficients for adherence on pain   severity. 
In the first OLS model, the dependent variable was pain 
severity at the 6 week follow-up and the independent vari-
ables were the same as in Model 1, yielding the cross-lagged 
regression coefficient for baseline adherence on 6 week 
pain severity. In the second OLS model, we replaced the 
dependent variable with the baseline pain severity score 
and replaced the independent variables for pain severity 
and adherence with the corresponding measures taken at 
the 6 week follow-up, yielding the cross-lagged regression 
coefficient for 6 week adherence on baseline pain severity. 
We compared these two regression coefficients using the 
method of Clogg et al.47 Supplementary and sensitivity 
analyses were also conducted to examine the effects of 
interactions between tendency to adhere and follow-up pain 
measurement time point, excluding baseline pain from the 
models, including adjustment for cancer treatment status 
(series of four dummy variables, one each for chemotherapy, 
hormonal therapy, radiotherapy, and surgical therapy), and 
removing variables from Model 2, one at a time, to consider 
their individual contributions.
Results
Of 3720 patients sent a recruitment letter, 3413 were excluded 
(1011 returned an opt-out postcard; 1015 could not be 
reached by telephone despite repeated calls; and 1387 were 
ineligible). The remaining 307 were randomized, and 265 
received their randomly allocated intervention. Of these, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27
Tendency to adhere and cancer pain
224 had at least one follow-up pain severity assessment after 
the baseline assessment plus complete data for other Model 
1 and 2 variables and were included in analyses.
Table 1 summarizes the characteristics of the current 
study sample. Subjects were predominantly women, non-
minority, and well educated. Breast cancer and metastatic 
cancer affected over 50% of the sample. The mean baseline 
MOS general adherence score was high. The study sample 
had relatively poor mental and, in particular, physical 
health status, manifested by a mean MCS-12 score about 
half a standard deviation below the general US popula-
tion mean, and a mean PCS-12 score about two standard 
deviations below the population mean. Mean pain severity 
was moderately high throughout the study but decreased 
during follow-up.
Table 2 shows the findings of the Model 1 analysis, 
adjusted only for basic sociodemographic characteristics, 
study group and site, pain assessment time point, and baseline 
pain. General tendency to adhere to provider-recommended 
treatments was significantly associated with pain severity 
over the 12 week follow-up period. A one standard devia-
tion increase in the tendency to adhere to treatment was 
associated with a 0.22-point adjusted mean decrease in pain 
severity (95% confidence interval [CI] 0.40, 0.03). Baseline 
pain was also significantly associated with follow-up pain 
severity. When baseline pain was excluded from Model 1, 
the association between tendency to adhere to treatment 
and subsequent pain was larger, such that a one standard 
deviation increase in tendency to adhere was associated 
with a 0.31-point adjusted mean reduction in pain (95% CI 
0.60, 0.04). There was no significant interaction between 
adherence tendency and follow-up pain measurement time 
point (P = 0.64). Adjusting for cancer treatment status did 
not substantively change Model 1 findings (data not shown 
but available on request).
The cross-lagged model analysis revealed no significant 
association between baseline pain severity and tendency to 
adhere at 6 weeks (cross-lagged regression coefficient for 
6 week adherence = 0.13, 95% CI = -0.07–0.32; P = 0.21), 
contrasting with the significant association observed between 
baseline tendency to adhere and 6 week pain severity (cross-
lagged regression coefficient for baseline adherence = -0.29, 
95% CI = -0.55 to -0.03; P = 0.03). The regression coeffi-
cient for baseline tendency to adhere was significantly larger 
than that for tendency to adhere at 6 weeks (chi-square = 5.59, 
degrees of freedom = 1, P = 0.02).
In the Model 2 analysis (Table 2), adjusting for all 
Model 1 variables plus characteristics that may influence 
Table 1 characteristics of study participants
Characteristic N = 224
Age, years, mean (sD) 58.7 (9.5)
Minority, % 28.1
Female, % 77.7
education, years completed, %
 # 12 29.0
  13–15 29.9
 $ 16 41.1
Living with a partner, % 62.1
experimental group, % 50.9
study site
  site 1 49.6
  site 2 47.8
  site 3 2.7
cancer type, %
  Breast 55.8
  Lung 18.3
  Other 25.9
Metastatic disease, % 56.3
cancer treatment status, %
  chemotherapy
    current or scheduled to begin within 2 weeks  33.0
    Previous 51.3
    none/unknown 15.6
  hormonal therapy
    current or scheduled to begin within 2 weeks  36.2
    Previous 10.3
    none/unknown 53.6
  radiotherapy
    current or scheduled to begin within 2 weeks 8.0
    Previous 51.3
    none/unknown 40.6
  surgical therapy
    scheduled to receive within 3 months 0.4
    Previous 81.7
    none/unknown 17.9
health status, mean (sD)
  Physical (Pcs-12) 32.6 (8.8)
  Mental (Mcs-12) 44.3 (10.1)
Pain control self-efficacy, mean (SD) 3.1 (1.0)
MOs general Adherence score, mean (sD)
  enrollment 5.1 (1.0)
  6 weeks 5.2 (1.0)
Pain severity, mean (sD)
enrollment 6.6 (1.8)
  Pre-intervention 6.4 (2.0)
  Post-intervention 6.3 (2.0)
  Post-visit 6.3 (2.0)
  2 weeks 6.2 (2.1)
  6 weeks 5.9 (2.2)
  12 weeks 5.7 (2.4)
Abbreviations: Mcs-12, short Form health survey Mental component summary; 
MOs,  Medical  Outcomes  study;  Pcs-12,  short  Form  health  survey  Physical 
component summary; sD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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tendency to adhere and/or pain severity (partner status, 
cancer type and degree of spread, physical and mental 
health, and pain control self-efficacy), the association 
between tendency to adhere and follow-up pain severity 
was attenuated and no longer statistically significant. This 
remained true when baseline pain severity was removed 
from the model and when adjustment for cancer treat-
ment status was included (data not shown but available 
on request).
In exploratory analyses removing covariates indi-
vidually from Model 2, only the omission of PCS-12 or 
MCS-12 scores (and not partner status or pain control self-
efficacy score) substantively increased the strength of the 
association between tendency to adhere and pain severity, 
changing the estimated regression coefficient for tendency to 
adhere from -0.14 (95% CI -0.31, 0.04, P = 0.12) in the full 
model to -0.18 (95% CI -0.36, -0.01, P = 0.04) and -0.18 
(95% CI -0.35, -0.01, P = 0.04), respectively.
Discussion
The relationship between tendency to adhere to provider-
recommended treatments and subsequent pain severity 
among cancer patients has not been previously examined. 
This is an important oversight, given the generally suboptimal 
state of cancer pain control,1,2 the high societal prevalence of 
serious misgivings about the safety of analgesics commonly 
prescribed to treat cancer pain,1,2,6,7 and the apparently low 
levels of adherence to recommended cancer pain treatment 
regimens.3,4 Our findings begin to address this important yet 
previously neglected relationship.
In a secondary observational analysis of prospective 
data from patients enrolled in an RCT of a cancer pain 
coaching intervention, we found patients’ general tendency 
to adhere to provider-recommended treatments at baseline 
predicted cancer pain severity over 12 weeks’ follow-up in 
a model adjusting for basic sociodemographic characteris-
tics, RCT-related variables, and baseline pain (Model 1). 
Table 2 relationship between participant characteristics and follow-up pain severity
Characteristic Model 1 parameter  
estimatea (95% CI)
P value Model 2 parameter  
estimatea (95% CI)
P value
Adherence -0.20 (-0.38, -0.03) 0.02 -0.14 (-0.31, 0.04) 0.12
Age 0.06 (-0.12, 0.23) 0.52 0.03 (-0.14, 0.20) 0.72
racial/ethnic minority 0.05 (-0.31, 0.41) 0.79 0.04 (-0.30, 0.39) 0.81
Female 0.12 (-0.28, 0.52) 0.56 0.13 (-0.34, 0.61) 0.58
education (ref = high school or less)
  some college 0.18 (-0.24, 0.61) 0.40 0.15 (-0.26, 0.56) 0.47
  college graduate -0.25 (-0.65, 0.15) 0.21 -0.23 (-0.62, 0.16) 0.25
experimental group -0.10 (-0.42, 0.22) 0.54 -0.04 (-0.35, 0.28) 0.82
study site (ref = site 1)
  site 2 -0.16 (-0.49, 0.16) 0.32 -0.28 (-0.59, 0.04) 0.09
  site 3 0.18 (-0.82, 1.18) 0.72 0.42 (-0.57, 1.40) 0.41
Pain measurement time point (ref = pre-intervention)
  Post-intervention -0.11 (-0.33, 0.12) 0.35 -0.11 (-0.33, 0.12) 0.35
  Post-visit -0.13 (-0.35, 0.09) 0.26 -0.13 (-0.35, 0.09) 0.26
  2 weeks -0.18 (-0.40, 0.05) 0.12 -0.18 (-0.41, 0.05) 0.12
  6 weeks -0.42 (-0.65, -0.19) ,0.01 -0.42 (-0.64, -0.19) ,0.01
  12 weeks -0.61 (-0.84, -0.38) ,0.01 -0.61 (-0.84, -0.38) ,0.01
Baseline pain severity 0.73 (0.64, 0.82) ,0.01 0.64 (0.54, 0.73) ,0.01
cancer type (ref = breast)
  Lung -0.13 (-0.59, 0.33) 0.57
  All others -0.16 (-0.62, 0.30) 0.51
Metastatic disease 0.32 (-0.03, 0.67) 0.07
Living with partner -0.18 (-0.51, 0.14) 0.27
Pcs-12 -0.04 (-0.06, -0.02) ,0.01
Mcs-12 -0.02 (-0.03, -0.00) 0.05
Pain control self-efficacy -0.01 (-0.19, 0.17) 0.92
Note: aParameter estimates are the estimated regression coefficients from a mixed effects multiple linear regression model.
Abbreviations: CI, confidence interval; MCS-12, Short Form Health Survey Mental Component Summary; PCS-12, Short Form Health Survey Physical Component 
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The     sociodemographic characteristics in this model (age, 
gender, race/ethnicity, and education) were included because 
each has been associated with pain15 and adherence22 in prior 
studies. Particularly in the context of the observed significant 
association between general tendency to adhere and pain 
severity, we considered that including baseline pain in the 
model, although conservative, might constitute overadjust-
ment, as some of the influence of adherence tendency on pain 
severity would likely have been exerted at the start of the 
study. Consistent with this reasoning, in an analysis omitting 
baseline pain from Model 1, there was an additional 0.1-point 
decrement in adjusted mean pain severity associated with a 
one standard deviation increase in tendency to adhere. On the 
other hand, not adjusting for baseline pain may   represent 
underadjustment. Thus, the “true” point estimate of the 
association between baseline general treatment adherence 
tendency and subsequent pain severity may lie somewhere 
between these values.
These findings are broadly consistent with those of a 
large number of prior studies employing a variety of adher-
ence measures, including measures of general tendency 
to adhere, and involving patients with diseases other than 
cancer and outcomes other than pain severity.8   Additionally, 
a cross-lagged model analysis revealed no significant 
association between baseline pain severity and 6 week 
adherence tendency, contrasting with the   aforementioned 
significant association between baseline adherence tendency 
and 6 week pain severity, and baseline tendency to adhere 
parameter estimate was significantly larger than the 6 week 
tendency to adhere parameter estimate. These findings sug-
gest that a simple “halo effect” due to underlying patient 
dispositional characteristics influencing both adherence 
tendency and pain severity is unlikely to account for the 
observed association between adherence tendency and 
subsequent pain severity. Rather, the temporal sequencing 
of the relationship (baseline adherence tendency associated 
with subsequent pain, but baseline pain not associated with 
subsequent adherence tendency) is consistent with a causal 
relationship. Thus, measurement of baseline tendency 
to adhere to recommended treatments may be useful in 
predicting pain severity over time among cancer patients. 
Furthermore, studies involving individuals with noncancer 
health conditions suggest “tendency to adhere” is a more 
mutable characteristic than the label might imply, and so 
might represent a useful therapeutic target. Future RCTs 
of interventions expressly designed to improve cancer 
pain control through salutary effects on tendency to adhere 
would be helpful to more definitively investigate these 
possibilities.
To further explore the relationship between adherence 
tendency and pain severity, we also created an expanded 
model that included all Model 1 variables as well as several 
personal characteristics likely to influence the tendency to 
adhere, pain severity, or both: partner status, mental and phys-
ical health status, and pain control self-efficacy (Model 2). 
These additional variables were included in the model based 
on previously demonstrated associations with pain14,16–21 as 
well as with adherence.23–36 In this model, patient tendency to 
adhere was no longer significantly associated with follow-up 
pain severity, and the inclusion of two variables in particular 
(physical and mental health status) appeared to account for 
this finding. This is again generally consistent with prior 
research involving patients with health conditions other 
than cancer, in which lower mental health status28–33and, 
particularly for more burdensome health conditions, lower 
physical health status34–36 have been associated with lower 
adherence estimates, including lower tendency to adhere as 
assessed with the MOS general adherence measure.33
One potential interpretation of this finding is that the 
general tendency to adhere to provider-recommended treat-
ments influences subsequent pain severity among cancer 
patients, and that physical and mental health statuses medi-
ate this effect. Individuals who assess themselves as being 
more likely to adhere to provider-recommended treatments 
may actually be more adherent to specific pain treatments 
(not measured in the current study). Better adherence could 
improve physical and mental health status, in turn leading 
to less “actual” pain (due to reduced physical illness burden) 
and reduced tendency to report severe pain (due to improved 
mental health and better coping). Alternatively, physical and 
mental health status may confound the relationship between 
tendency to adhere and subsequent cancer pain severity. Such 
confounding could reflect the influence of relatively fixed 
underlying dispositional characteristics (eg, optimism on 
the “positive” side and neuroticism on the “negative” side). 
Such characteristics are likely to influence patient responses 
to each of the relevant self-report measures (adherence ten-
dency, health status, pain severity), which seek to capture 
respondent standing on conceptually different yet, in reality, 
partially overlapping constructs. Including the SF-12 in our 
models might also result in overadjustment, as the measure 
includes one item concerning pain (asking respondents 
to rate how much pain interfered with their normal work 
during the preceding 4 weeks). Another potential source Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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of confounding is that individuals with poor health status, 
reflecting poor control of their health conditions, may also 
have more pain, which might impair their ability to adhere 
to recommended treatments. In the context of observational 
data such as those available here, the distinction between 
mediation and confounding cannot be determined,48 yet the 
research and clinical implications of each explanation would 
be somewhat different. Future studies will be required to 
clarify this issue.
Our study had a number of strengths, including a pro-
spective design, the use of rigorous analytic methods, and a 
sample that included patients with a range of cancer types 
and severities. Our study also had some limitations. Though 
our analyses examined temporal associations between adher-
ence and pain severity, causality cannot be inferred from 
these observational relationships. The study data were also 
drawn from a sample of English-speaking cancer patients 
cared for by cancer specialists in one metropolitan area, so 
the findings may or may not be generalize to other patients, 
physicians, or geographic regions. Finally, the parent RCT 
from which the study data were drawn included a single 
adherence measure assessing patients’ global tendency to 
adhere to provider-recommended treatments. Thus, we were 
unable to examine the relationship between actual patient 
adherence to specific recommended pain treatments, such 
as individual prescription or over-the-counter pain medica-
tions, and pain severity. The findings of analyses similar to 
ours but that focus on the effects of adherence to specific 
recommended treatments might differ.
In conclusion, in a secondary analysis of data from an 
RCT of cancer patient coaching intervention, we found that 
baseline general patient tendency to adhere to provider-
recommended treatments was significantly associated with 
cancer pain severity over 12 weeks when adjusting for basic 
sociodemographic characteristics, RCT-related variables, 
and baseline pain. Furthermore, the results of a cross-lagged 
analysis suggested this association is unlikely to merely 
reflect underlying patient dispositional characteristics that 
influence both adherence tendency and pain severity. If 
confirmed in other studies designed specifically to examine 
causality, this finding would suggest that general tendency 
to adhere to provider-recommended treatments might be 
useful as a predictor of subsequent cancer pain severity and 
as a target of interventions to improve cancer pain control. 
Tempering this finding somewhat, we also found that after 
further adjusting for health status, the association between 
adherence tendency and pain severity was no longer signifi-
cant. Thus, health status either mediated or confounded the 
adherence tendency/pain severity relationship, with each of 
these potential interpretations having somewhat different 
research and clinical implications. Further prospective stud-
ies designed to clarify the nature of the relationships among 
tendency to adhere, health status, and pain severity among 
cancer patients appear warranted.
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